Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;52(4):1246-9.
doi: 10.1128/JCM.03119-13. Epub 2014 Jan 29.

Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease

Moritz Jansson  1 , Marcus Beissner, Richard Odame Phillips, Kossi Badziklou, Ebekalisai Piten, Issaka Maman, Fred Stephen Sarfo, Kristina Lydia Huber, Agata Rhomberg, Dominik Symank, Magdalena Wagner, Franz Wiedemann, Jörg Nitschke, Abiba Banla Kere, Karl-Heinz Herbinger, Ohene Adjei, Thomas Löscher, Gisela Bretzel
Affiliations

Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease

Moritz Jansson et al. J Clin Microbiol. 2014 Apr.

Abstract

This study evaluates a novel assay for detecting rifampin resistance in clinical Mycobacterium ulcerans isolates. Although highly susceptible for PCR inhibitors in 50% of the samples tested, the assay was 100% M. ulcerans specific and yielded >98% analyzable sequences with a lower limit of detection of 100 to 200 copies of the target sequence.

PubMed Disclaimer

References

    1. Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundoté A, Cottin J, Ladikpo T, Ruf T, Ji B. 2011. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin. Infect. Dis. 52:94–96. 10.1093/cid/ciq072 - DOI - PubMed
    1. Alffenaar JW, Nienhuis WA, de Velde F, Zuur AT, Wessels AM, Almeida D, Grosset J, Adjei O, Uges DR, van der Werf TS. 2010. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob. Agents Chemother. 54:3878–3883. 10.1128/AAC.00099-10 - DOI - PMC - PubMed
    1. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS. 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375:664–672. 10.1016/S0140-6736(09)61962-0 - DOI - PubMed
    1. Beissner M, Piten E, Maman I, Symank D, Jansson M, Nitschke J, Amekuse K, Kobara B, Wiedemann F, Hoffmann H, Diefenhardt A, Badziklou K, Banla Kere A, Löscher T, Bretzel G. 2012. Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy—a case report from Togo. PLoS Negl. Trop. Dis. 6:e1747. 10.1371/journal.pntd.0001747 - DOI - PMC - PubMed
    1. Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, Johnson RC, Pluschke G. 2011. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl. Trop. Dis. 5:e1252. 10.1371/journal.pntd.0001252 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources